Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 1 trial of QTX3034, an oral KRAS G12D inhibitor, combined with cetuximab and chemotherapy showed a 50% response rate in KRAS G12D–mutated colorectal cancer patients — double the rate seen without chemo. Side effects were manageable, and no patients stopped treatment due to toxicity. The combo has already earned FDA fast track designation.
A new drug combination is generating early excitement in the colorectal cancer space. Phase 1 data presented at the 2026 ESMO Congress show that QTX3034 — an oral inhibitor that preferentially targets the KRAS G12D mutation — combined with cetuximab and the chemotherapy backbone mFOLFOX6, achieved a 50% objective response rate (ORR) in 10 evaluable patients with KRAS G12D–mutated colorectal cancer (CRC), including one complete response. By comparison, the doublet of QTX3034 plus cetuximab alone yielded a 25% ORR in 20 evaluable patients.
The safety profile was largely manageable. Most side effects were grade 1 or 2, and while grade 3+ events rose from 24% (doublet) to 43% (triplet), no patients discontinued the triplet due to toxicity. Dose reductions increased modestly from 14% to 29% — consistent with other drugs in this class.
By the Numbers
Why it matters: KRAS G12D mutations are among the most common — and historically undruggable — drivers of CRC. These are the first data combining a RAS inhibitor with a chemotherapy backbone in this setting, and the FDA fast track designation signals regulatory momentum. Investigators are now eyeing earlier lines of therapy, which could reshape treatment sequencing for this patient population.
